clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02960906 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | France | Q142 |
P582 | end time | 2020-05-01 | |
P2899 | minimum age | 18 | |
P1132 | number of participants | 150 | |
P6153 | research site | Centre François Baclesse | Q50036603 |
Institut Gustave Roussy | Q266227 | ||
hôpital Foch | Q3145155 | ||
Institut Claudius Regaud | Q3151727 | ||
L'Institut Mutualiste Montsouris | Q3152361 | ||
P1813 | short name | BIONIKK | |
P580 | start time | 2017-05-31 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer |